Clinical Edge Journal Scan

Elevated IL-23 levels associated with psychiatric disorders in PsA


 

Key clinical point: In patients with psoriatic arthritis (PsA), serum interleukin-23 (IL-23) levels were elevated and significantly correlated with disease activity (DA), depression, and anxiety.

Major finding: Serum IL-23 levels were higher in patients with PsA vs healthy volunteers without PsA (225.19 vs 118.12 pg/mL; P < .0001), and a significantly higher proportion of patients vs volunteers reported anxiety (45% vs 20%) and depression (35% vs 15%; both P < .0001). Serum IL-23 levels were positively correlated with Disease Activity Index for Psoriatic Arthritis (correlation coefficient [r] 0.959), Hospital Anxiety and Depression Scale (HADS) anxiety (r 0.932), and HADS depression (r 0.934; all P = .0001) scores.

Study details: Findings are from an observational case-control study including 80 patients with PsA and 80 matched healthy volunteers.

Disclosures: This study was funded by The Science, Technology & Innovation Funding Authority, Egypt, in cooperation with The Egyptian Knowledge Bank. The authors declared no conflicts of interest.

Source: Tabra SA et al. Serum interleukin-23 levels: Relation to depression, anxiety, and disease activity in psoriatic arthritis patients . Clin Rheumatol. 2022 (Jul 21). Doi: 10.1007/s10067-022-06300-1

Recommended Reading

Biosimilar-to-biosimilar switches deemed safe and effective, systematic review reveals
MDedge Rheumatology
FDA approves adalimumab-bwwd biosimilar (Hadlima) in high-concentration form
MDedge Rheumatology
PsA: Bimekizumab is well tolerated and effective in the long-term
MDedge Rheumatology
Golimumab effective as second-line anti-TNFα treatment in the real-world
MDedge Rheumatology
Nail disease and dactylitis influence treatment response in patients receiving etanercept or methotrexate
MDedge Rheumatology
Nail dystrophy predicts response to secukinumab in PsA patients with axial manifestations
MDedge Rheumatology
Clinically meaningful improvement in PRO with risankizumab vs placebo in PsA
MDedge Rheumatology
Robust and consistent improvement in HRQoL with guselkumab
MDedge Rheumatology
Long-term safety and efficacy of risankizumab in PsA
MDedge Rheumatology
PsA remission depends on patient perception and is multidimensional
MDedge Rheumatology